Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients with Solid Tumours

Trial Identifier: D0816C00025
Sponsor: AstraZeneca
NCTID:: NCT04236414
Start Date: January 2020
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Clayton, AU, 3168
AU Nedlands, AU, 6009
AU Randwick, AU, 2031
CA, QC Montreal, QC, CA, H4A 3J1
DE Heidelberg, DE, 69120
DE Mainz, DE, 55131
DE Mainz, DE, 55131
DE Mainz, DE, 55131
DE Mainz, DE, 55131
DE Mainz, DE, 55131
DE Mainz, DE, 55131
DE Mainz, DE, 55131
DE Mainz, DE, 55131
DE Mainz, DE, 55131
DE Mainz, DE, 55131
DE Mainz, DE, 55131
DK København Ø, DK, 2100
ES Barcelona, ES, 08950
ES Barcelona, ES, 08035
ES Madrid, ES, 28046
ES Madrid, ES, 28009
ES Valencia, ES, 46026
FR Lille, FR, 59000
FR Marseille, FR, 13385
FR Paris, FR, 75005
FR Toulouse, FR, 31300
FR Villejuif Cedex, FR, 94805
GB Birmingham, GB, B4 6NH
GB Glasgow, GB, G51 4TF
GB Leeds, GB, LS1 3EX
GB Sutton, GB, SM2 5PT
HU Budapest, HU, 1094
IL Haifa, IL, 3109601
IL Petah Tikva, IL, 4920235
IT ROMA, IT, 00165
KR Seoul, KR, 06351
KR Seoul, KR, 03080
KR Seoul, KR, 05505
PL Szczecin, PL, 71-252
PL Warszawa, PL, 01-211
RU Moscow, RU, 117198
RU Saint Petersburg, RU, 197022
UA Lviv, UA, 79035
US, NC Charlotte, NC, US, 28203